In less than three weeks, American medicine produced two milestones worth noticing.
On Aug. 5, the Food and Drug Administration approved MFLUSIVA, Moderna’s influenza vaccine for adults 50 and older — the first flu vaccine in the United States built with messenger RNA, or mRNA.
Real journalism.Trusted by millions.
Unlimited access to in-depth reporting, expert analysis, and the stories that shape our country.
Subscribe Now
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.
